Myriam J. Curet, M.D.
Director at INSP
Board
About Myriam J. Curet, M.D.
Myriam J. Curet, M.D. (age 68) is an independent Class III director of Inspire Medical Systems, Inc. (INSP) since 2023. She serves as Executive Vice President and Chief Medical Officer at Intuitive Surgical and is a Clinical Professor of Surgery at Stanford University, bringing deep clinical, regulatory, and medical device expertise. At Inspire, she sits on the Nominating & Corporate Governance Committee and the Quality, Product Supply, and Technology Committee, and is affirmed independent under NYSE rules. Attendance in 2024 was 100% for all directors and committee meetings on which they served.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Intuitive Surgical | EVP & Chief Medical Officer | 2017–present | Led development of clinical evidence, physician education, reimbursement and regulatory activities—skills core to board oversight in quality/regulatory matters |
| Intuitive Surgical | Chief Medical Advisor | 2005–2014 | Senior clinical advisory leadership supporting regulatory and adoption strategies |
| Stanford University | Clinical Professor of Surgery | 2015–present | Academic leadership; informs clinician engagement and evidence generation oversight |
| University of New Mexico | Associate Professor of Surgery | 1994–2000 | Academic and clinical leadership |
| Indian Health Service / Gallup Indian Medical Center | Various roles / Medical Deputy Director | Not specified | Public health and hospital leadership experience |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Stereotaxis | Director | 2021–present | Current public company directorship |
| Nektar Therapeutics | Director | 2019–2024 | Prior public company directorship |
Board Governance
- Independence: Board determined Dr. Curet is independent (8 of 9 directors independent).
- Committee assignments (as of Mar 18, 2025): Nominating & Corporate Governance; Quality, Product Supply, and Technology (QPS&T). Not a chair.
- Attendance and engagement: In 2024, every incumbent director attended all Board and applicable committee meetings; all directors attended the 2024 annual meeting. Executive sessions are held regularly.
- Board leadership: Combined Chair/CEO structure with a Lead Independent Director (Gary L. Ellis) providing independent oversight.
- Governance structure and changes: Board formed a new standing QPS&T Committee in Feb 2025, enhancing oversight of quality, supply, regulatory compliance, and technology—aligned with Dr. Curet’s expertise.
- Stockholder feedback context: Say‑on‑pay approval at 2024 annual meeting was ~97% FOR; Board conducts regular investor engagement on governance.
Fixed Compensation (Director)
| Component | Amount (USD) | Detail |
|---|---|---|
| Annual cash retainer (2024) | $50,000 | Standard non‑employee director cash retainer |
| Committee membership cash (2024) | $7,500 | Nominating & Corporate Governance non‑chair member |
| Total cash fees (2024) | $57,500 | Fees earned/paid in cash for 2024 |
Policy notes:
- Additional lead director retainer added in May 2024 ($32,000; not applicable to Dr. Curet).
- In Feb 2025, QPS&T Committee retainers added: Chair $15,000; member $7,500 (applies going forward).
Performance Compensation (Director)
| Equity Element | 2024 Value (USD) | Vesting | Notes |
|---|---|---|---|
| Annual RSU grant | $180,000 | Vests on first anniversary of grant date | Granted at the annual meeting; time‑based vesting only (no performance metrics) |
| Initial RSU grant (on first joining Board) | $270,000 | Vests in three equal annual installments | Applies at initial appointment; time‑based vesting |
| Unvested RSUs held at 12/31/2024 | 1,638 units | As scheduled per grant terms | Director‑level aggregate shown for each director |
- No stock options were granted to non‑employee directors in 2024; Dr. Curet had no options outstanding as of year‑end 2024.
- Director equity awards are time‑based; Inspire does not disclose any director‑level performance metrics tied to compensation.
Other Directorships & Interlocks
| Company | Overlap/Interlock Risk | Notes |
|---|---|---|
| Stereotaxis | None disclosed | Board biography only; no related‑party transactions disclosed with Inspire |
| Nektar Therapeutics (former) | None disclosed | Ended 2024; no related‑party transactions disclosed with Inspire |
- Related‑party transactions: Inspire discloses a CEO‑related suite cost‑sharing arrangement; no transactions involving Dr. Curet are disclosed.
Expertise & Qualifications
- Medical professional and surgeon with three decades in healthcare and academia—strong clinician engagement and education perspective.
- Industry and technology expertise from senior leadership at Intuitive Surgical and service on medical device/biopharma boards.
- Legal/compliance oversight experience leading clinical evidence, physician education, reimbursement, and regulatory programs—directly relevant to QPS&T and governance oversight.
Equity Ownership
| Category | Amount | Notes |
|---|---|---|
| Beneficial ownership (common shares) | 2,100 shares | As of March 4, 2025 |
| Unvested RSUs | 1,638 units | As of Dec 31, 2024 |
| Stock options outstanding | 0 | As of Dec 31, 2024 |
| Ownership guideline | 3x annual cash retainer for directors | Must be attained within 5 years; includes certain unvested RSUs in calculation |
| Compliance status | In compliance | As of 12/31/2024, all non‑employee directors had attained the minimum ownership; exceptions listed were executives, not directors |
| Hedging/pledging | Prohibited | Company policy bans hedging; pledging requires pre‑approval (no pledging disclosed for Dr. Curet) |
Governance Assessment
- Fit-for-purpose committee placement: Service on Nominating & Corporate Governance and the newly formed QPS&T Committee leverages her clinical, regulatory, and technology background—supports board effectiveness in core risk areas (quality, regulatory, supply, R&D).
- Alignment and incentives: Director pay skews to equity via annual time‑vested RSUs ($180,000 in 2024) with modest cash fees ($57,500), aligning interests with shareholders; no director options in 2024, reducing risk of option‑related incentives.
- Engagement and independence: Board affirmed independence; 2024 attendance was 100% for board and applicable committees; all directors attended the 2024 annual meeting—positive engagement signal.
- Conflicts and related‑party exposure: No related‑party transactions or interlocks involving Dr. Curet disclosed; anti‑hedging/pledging policies in place; ownership guidelines met—low conflict risk.
Red flags
- None disclosed specific to Dr. Curet (no attendance issues, no related‑party transactions, no hedging/pledging, compliant ownership).